- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically ...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...
Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans ...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
Pfizer Inc. has announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union, marki...
ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...
CF, a genetic disorder triggered by mutations in the CFTR gene, leads to the accumulation of thick mucus in vital organs such as the lungs and dige...
In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA p...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
© 2025 Biopharma Boardroom. All Rights Reserved.
